Search
Mirum Pharmaceuticals Inc
MIRMAdd to Watchlist
112.680USD
+5.800+5.43%
Market hours （ET）Quotes delayed by 15 min
5.85BMarket Cap
LossP/E TTM
More Details of Mirum Pharmaceuticals Inc Company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Mirum Pharmaceuticals Inc Info
Ticker SymbolMIRM
Company nameMirum Pharmaceuticals Inc
IPO dateJul 18, 2019
CEOPeetz (Christopher)
Number of employees322
Security typeOrdinary Share
Fiscal year-endJul 18
Address989 East Hillsdale Boulevard, Suite 300
CityFOSTER CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94404
Phone16506674085
Websitehttps://mirumpharma.com/
Ticker SymbolMIRM
IPO dateJul 18, 2019
CEOPeetz (Christopher)
Company Executives of Mirum Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
389.76K
+5.43%
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
49.74K
+13.19%
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
35.38K
+42.26%
Dr. Joanne Quan, M.D.
Dr. Joanne Quan, M.D.
Chief Medical Officer
Chief Medical Officer
28.65K
+55.50%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.70K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Director
Independent Director
5.70K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
Independent Director
Independent Director
--
--
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
--
--
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
389.76K
+5.43%
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
49.74K
+13.19%
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
35.38K
+42.26%
Dr. Joanne Quan, M.D.
Dr. Joanne Quan, M.D.
Chief Medical Officer
Chief Medical Officer
28.65K
+55.50%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.70K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
By BusinessUSD
Name
Revenue
Proportion
Livmarli
360.01M
69.06%
Bile Acid Medicines
161.31M
30.94%
License and other revenue
0.00
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Livmarli
360.01M
69.06%
Bile Acid Medicines
161.31M
30.94%
License and other revenue
0.00
0.00%
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
12.59%
Janus Henderson Investors
9.95%
BlackRock Institutional Trust Company, N.A.
5.13%
Vanguard Capital Management, LLC
3.96%
State Street Investment Management (US)
3.52%
Other
64.85%
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
12.59%
Janus Henderson Investors
9.95%
BlackRock Institutional Trust Company, N.A.
5.13%
Vanguard Capital Management, LLC
3.96%
State Street Investment Management (US)
3.52%
Other
64.85%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
35.04%
Investment Advisor
34.03%
Hedge Fund
16.35%
Private Equity
13.71%
Research Firm
4.01%
Venture Capital
2.55%
Individual Investor
1.37%
Pension Fund
0.65%
Sovereign Wealth Fund
0.43%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
541
68.01M
111.53%
+4.80M
2025Q4
516
59.67M
115.53%
-2.23M
2025Q3
468
57.20M
111.61%
-6.92M
2025Q2
458
58.36M
116.21%
-4.59M
2025Q1
454
57.59M
116.38%
-4.84M
2024Q4
425
56.60M
115.52%
-10.44M
2024Q3
408
56.58M
118.52%
-12.05M
2024Q2
398
57.22M
121.33%
-10.51M
2024Q1
391
57.27M
121.82%
-5.03M
2023Q4
376
54.05M
116.10%
-4.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
7.68M
12.73%
+884.56K
+13.02%
Jan 23, 2026
Janus Henderson Investors
6.07M
10.05%
+1.07M
+21.36%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
3.13M
5.19%
+97.33K
+3.21%
Dec 31, 2025
State Street Investment Management (US)
2.14M
3.55%
+797.09K
+59.18%
Dec 31, 2025
Eventide Asset Management, LLC
2.09M
3.47%
-428.98K
-17.01%
Dec 31, 2025
BVF Partners L.P.
1.50M
2.48%
--
--
Dec 31, 2025
T. Rowe Price Associates, Inc.
1.38M
2.28%
+133.02K
+10.69%
Dec 31, 2025
Novo Holdings A/S
1.26M
2.09%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Virtus LifeSci Biotech Products ETF
2.37%
Invesco Dorsey Wright Healthcare Momentum ETF
1.52%
ALPS Medical Breakthroughs ETF
1.51%
Federated Hermes MDT Small Cap Core ETF
1.14%
First Trust Innovation Leaders ETF
1.03%
Tema Heart & Health ETF
1.02%
First Trust Small Cap Growth AlphaDEX Fund
0.68%
State Street SPDR S&P Biotech ETF
0.58%
First Trust NASDAQ Pharmaceuticals ETF
0.52%
JPMorgan Fundamental Data Science Small Core ETF
0.43%
View more
Virtus LifeSci Biotech Products ETF
Proportion2.37%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.52%
ALPS Medical Breakthroughs ETF
Proportion1.51%
Federated Hermes MDT Small Cap Core ETF
Proportion1.14%
First Trust Innovation Leaders ETF
Proportion1.03%
Tema Heart & Health ETF
Proportion1.02%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.68%
State Street SPDR S&P Biotech ETF
Proportion0.58%
First Trust NASDAQ Pharmaceuticals ETF
Proportion0.52%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.43%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
